A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children’s Oncology Group Phase I Consortium Report

BACKGROUND: Aflibercept is a novel decoy receptor that efficiently neutralizes circulating vascular endothelial growth factor (VEGF). A pediatric phase 1 trial was performed to define the dose limiting toxicities (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of aflibercept. METHODS:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bender, Julia Glade, Blaney, Susan M., Borinstein, Scott, Reid, Joel M., Baruchel, Sylvain, Ahern, Charlotte, Ingle, Ashish M., Yamashiro, Darrell J., Chen, Alice, Weigel, Brenda, Adamson, Peter C., Park, Julie R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3445751/
https://ncbi.nlm.nih.gov/pubmed/22791883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-0078
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados